# Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat

> **NCT03823131** · PHASE2 · TERMINATED · sponsor: **Chase Heaton, MD** · enrollment: 14 (actual)

## Conditions studied

- Metastatic Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Squamous Cell Carcinoma
- Unresectable Head and Neck Squamous Cell Carcinoma

## Interventions

- **DEVICE:** ImmunoPulse
- **DRUG:** Epacadostat
- **DRUG:** Pembrolizumab
- **BIOLOGICAL:** CORVax
- **DRUG:** Tavokinogene telseplasmid

## Key facts

- **NCT ID:** NCT03823131
- **Lead sponsor:** Chase Heaton, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-02
- **Primary completion:** 2022-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Treatment Ineffective
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03823131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03823131, "Optimizing Antitumor Immunity Using Plasmid Electroporation, Pembrolizumab, and Epacadostat". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03823131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*